Monon Bioventures receives SBIR grant to develop glioblastoma therapeutic created at Purdue
Summary
Monon Bioventures LLC has received a one-year, $398,314 Phase I Small Business Innovation Research, or SBIR grant from the National Cancer Institute to demonstrate the feasibility of manufacturing a glioblastoma therapeutic created at the Purdue University College of Pharmacy. "Joe Trebley, president and CEO of Monon Bioventures, which is housed in the Indiana Center for Biomedical Innovation, said the federal funds for Matosevics work have the potential to bring hope to patients suffering from glioblastoma. "Monon Bioventures will work on the treatment with Matosevics laboratory at Purdue and Genezen, a viral vector and gene therapy contract development and manufacturing organization, or CDMO. After receiving the FDAs feedback, the company will look to finance the project further.Trebley credited the NCI and its SBIR program for critical support of innovation and discovery in the early development phase of cancer research. "The grants are highly competitive, yet critical to funding novel potential therapeutics that translate out of academic labs," he said.Matosevic disclosed his glioblastoma treatment to the Purdue Research Foundation Office of Technology Commercialization, which has applied for a patent to protect the intellectual property.